Nilotinib Zentiva (Nilotinib)

Nilotinib blocks the activity of the BCR‑ABL tyrosine kinase as well as related kinases c‑KIT and PDGFR. By inhibiting these enzymes, it disrupts signaling pathways that promote uncontrolled cell division, leading to reduced proliferation of leukemic cells and induction of programmed cell death.

The specific dose of Nilotinib Zentiva is determined by the prescribing physician based on the patient’s disease phase, prior treatments, and individual health factors. Only a qualified healthcare professional can set the appropriate dosing regimen.

Nilotinib is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should not be used during pregnancy, and effective contraception is required. Breastfeeding is not recommended while on treatment because the drug may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor with higher potency against many resistant BCR‑ABL mutations compared with first‑generation agents like imatinib. It also has activity against c‑KIT and PDGFR, but its safety profile includes a higher risk of QT prolongation, requiring cardiac monitoring.

Store Nilotinib Zentiva tablets at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Do not refrigerate or freeze the tablets, and keep them out of reach of children.

Nilotinib Zentiva is taken orally, usually as whole tablets with a low‑fat meal. The tablets should be swallowed with water and not crushed or chewed. Patients should follow the dosing schedule and dietary instructions provided by their prescriber.

The most serious risks include QT interval prolongation, which can lead to life‑threatening arrhythmias, severe liver injury, and pancreatitis. Patients should undergo regular ECG monitoring, liver function tests, and be educated on symptoms that require immediate medical attention.

Nilotinib should not be used by patients with a known hypersensitivity to nilotinib or any of its excipients, those with a history of prolonged QT interval, uncontrolled cardiac disease, or severe hepatic impairment. Pregnant women and breastfeeding mothers should also avoid the medication.